Clicky

IDEAYA Biosciences, Inc.(IDYA)

Description: IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.


Keywords: Medicine Biotechnology Clinical Medicine Drug Discovery Biomarkers Medical Test Molecular Diagnostics Medical Genetics Targeted Therapy Precision Medicine Systems Biology Synthetic Lethality

Home Page: www.ideayabio.com

IDYA Technical Analysis

7000 Shoreline Court
South San Francisco, CA 94080
United States
Phone: 650 443 6209


Officers

Name Title
Mr. Yujiro S. Hata Co-Founder, CEO, Pres & Director
Mr. Paul A. Stone Sr. VP, CFO & Principal Accounting Officer
Dr. Michael A. White Ph.D. Sr. VP & Chief Scientific Officer
Dr. Jeffrey Hager Ph.D. Co -Founder
Mr. Andres Ruiz Briseno CPA VP and Head of Bus. Operations & IR
Mr. Jason S. Throne J.D., Esq. Sr. VP, Gen. Counsel & Company Sec.
Dr. Paul A. Barsanti Ph.D. Sr. VP & Head of Drug Discovery
Dr. Matthew Maurer M.D. VP and Head of Medical Affairs & Clinical Oncology
Mr. Mick O'Quigley Sr. VP of Devel. Operations
Dr. Darrin M. Beaupre M.D., Ph.D. Sr. VP & Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 4.649
Trailing PE: 0
Price-to-Book MRQ: 2.2128
Price-to-Sales TTM: 16.2851
IPO Date: 2019-05-23
Fiscal Year End: December
Full Time Employees: 95
Back to stocks